EFFECTS OF DILAZEP ON FIBRINOLYTIC SYSTEM IN ANIMALS. II. ENHANCING EFFECT OF DILAZEP ON PLASMINOGEN ACTIVATOR RELEASE IN THE ISOLATED PERFUSED PIG EAR
スポンサーリンク
概要
- 論文の詳細を見る
The influence of drugs on the release of plasminogen activator was studied in the isolated perfused pig ear. The pig ear was perfused with oxygenated Tyrode's solution pH 7.4,at 37℃ via main artery and perfusate from the veins was collected at 2 min intervals. The drug was injected into a rubber tube connected in the front of arteria cannula, and the fibrinolytic activity of perfusate collected was measured by the fibrin plate method using plasminogen-containing bovine fibrinogen. Under the test condition, dilazep enhanced plasminogen activator release (PA release) in a dose-dependent fashion ranging 10 to 100 μg, however, it did not affect the perfusion pressure. Hypotensors, namely acetylcholine (0.1-3μg), bradykinin (0.1-3μg) and histamine (0.1-3μg) enhanced also the PA release in a dose-dependent fashion with no effects on perfusion pressure. Vasoconstricting drugs, namely phenylephrine (0.3-10 μg), norepinephrine (0.1-3 μg) and serotonin (0.1-3μg) exerted hypertensive effects on perfusion pressure in a dose-dependent fashion, however, it did not cause the PA release.
- 公益社団法人日本薬学会の論文
著者
関連論文
- Binding of Human Tissue Plasminogen Activator (t-PA) to Blood Clots and Clot-Lytic Activity of Clot-Bound t-PA
- Thrombolytic Effect of Tissue Plasminogen Activator in a Cerebral Embolic Model
- Localization of Tissue Plasminogen Activator on Experimental Microthrombi in Rats. Microautoradiographic Observations
- Localization of Tissue Plasminogen Activator on Experimental Thrombi in Rats
- EFFECTS OF DILAZEP ON FIBRINOLYTIC SYSTEM IN ANIMALS. II. ENHANCING EFFECT OF DILAZEP ON PLASMINOGEN ACTIVATOR RELEASE IN THE ISOLATED PERFUSED PIG EAR
- EFFECTS OF DILAZEP ON FIBRINOLYTIC SYSTEM IN ANIMALS. I. ENHANCEMENT OF FIBRINOLYTIC ACTIVITY BY ADMINISTERED DILAZEP IN EX VIVO EXPERIMENT
- Effects of Salt-loading on the Onset of Stroke and the Development of Cerebral Lesions in SHRSP
- Possibility of the Low Defensive Fibrinolysis in SHRSP
- Potential effectiveness of minidose aspirin combined with dilazep in anti-platelet therapy.